文献速递银屑病与炎症性皮肤病

大型人群队列中血清25-羟基维生素D水平与银屑病的关联

The association between serum 25-hydroxyvitamin D levels and psoriasis in a large population-based cohort: a cross-sectional analysis of The Tromsø Study 2015-16.
PubMed 文献 · Br J Dermatol · 2024-01-01

2088人(10.7%)报告终生银屑病,1179人(6.0%)报告过去12个月活动性银屑病。25(OH)D与终生银屑病无显著关联,但BMI>27.5 kg m-2与25(OH)D<25 nmol L-1对活动性银屑病存在超相加交互作用(OR 1.92,95%CI 1.18-3.12)。

要点

  • 25(OH)D每升高10 nmol L-1与终生银屑病无显著关联(OR 1.02,95%CI 0.99-1.04)。
  • BMI>27.5 kg m-2且25(OH)D<25 nmol L-1者活动性银屑病风险估计增加92%。
  • 超重银屑病患者随访中可考虑提供预防维生素D缺乏的建议。

核心结论

  • 大型人群队列未发现25(OH)D与银屑病存在显著关联。
  • 高BMI与维生素D缺乏联合对活动性银屑病存在超相加效应,估计风险增加92%。

研究设计与样本

  • 采用分数多项式评估25(OH)D与银屑病关系的形状,逻辑回归估计终生和活动性银屑病的OR。
  • 调整模型包括采血月份、BMI、年龄和性别,并探索BMI与25(OH)D的交互作用。

主要发现

  • 2088人(10.7%)报告终生银屑病,1179人(6.0%)报告过去12个月活动性银屑病。
  • 25(OH)D与终生银屑病无显著关联:每升高10 nmol L-1的OR为1.02(95%CI 0.99-1.04)。
  • 25(OH)D与活动性银屑病的关系提示非线性,但模型不显著(P=0.098)。
  • BMI>27.5 kg m-2与25(OH)D<25 nmol L-1对活动性银屑病存在超相加效应:OR 1.92(95%CI 1.18-3.12);对终生银屑病无此效应:OR 1.41(95%CI 0.93-2.15)。
  • 未发现BMI与25(OH)D之间的双向交互作用证据。

关键数值与推荐

  • 平均25(OH)D水平63.4 nmol L-1(SD 21.9)。

临床怎么用

  • 超重银屑病患者随访中可考虑提供预防维生素D缺乏的建议。

局限性

  • 分析可能把握度不足,无法检测25(OH)D低值范围内的阈值效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Case-control studies indicate an association between lower serum 25-hydroxyvitamin D [25(OH)D] levels and psoriasis. Data from larger population-based cohorts including mild cases are sparse. OBJECTIVES: To investigate the association between 25(OH)D and psoriasis in a large population-based cohort, and assess possible effect modification by overweight. METHODS: Data from the Tromsø Study 2015-16 (Tromsø7), which included 19 520 participants from the general population aged 40-79 years, were subjected to a cross-sectional analysis. We assessed the shapes of the relationships between 25(OH)D and psoriasis using fractional polynomials. Odds ratios (ORs) for lifetime and active psoriasis were estimated using logistic regression. Adjusted models included month of blood sampling, body mass index (BMI), age and sex. Two-way and additive interaction between BMI and 25(OH)D were explored. RESULTS: From a total of 19 520 participants [10 203 women (52.3%); mean age 56.3 years (SD 10.4); mean 25[OH]D, 63.4 nmol L-1 (SD 21.9)], 2088 (10.7%) reported lifetime psoriasis and 1179 (6.0%) reported active psoriasis the past 12 months. There was no association between 25(OH)D and lifetime psoriasis [OR per 10 nmol L-1 increase in 25(OH)D 1.02, 95% confidence interval (CI) 0.99-1.04]. The relationship between 25(OH)D and active psoriasis was suggested to be nonlinear, but the model was not significant (P = 0.098). There was evidence for a superadditive effect (i.e. larger than the sum of the factors) of BMI > 27.5 kg m-2 and 25(OH)D < 25 nmol L-1 on the odds for active psoriasis (OR 1.92, 95% CI 1.18-3.12), but not for lifetime psoriasis (OR 1.41, 95% CI 0.93-2.15). There was no evidence for two-way interaction between BMI and 25(OH)D. CONCLUSIONS: This large population-based study found no significant relationship between 25(OH)D and psoriasis. The analysis may have been underpowered to detect a threshold effect in the lower 25(OH)D spectrum. Interaction analysis indicates that high BMI and vitamin D deficiency combined increase the odds of active psoriasis more than the sum of these factors, with an estimated 92% higher odds for active psoriasis in participants with BMI > 27.5 kg m-2 and 25(OH)D < 25 nmol L-1. Providing advice to prevent vitamin D deficiency may be considered in the follow-up of overweight patients with psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Jenssen M, Furberg AS, Jorde R, et al. The association between serum 25-hydroxyvitamin D levels and psoriasis in a large population-based cohort: a cross-sectional analysis of The Tromsø Study 2015-16. Br J Dermatol. 2024. PMID: 38015798. doi:10.1093/bjd/ljad472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。